Who May Be at Risk for Tysabri-Related PML?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Education to Targeted Risk Assessment

If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). This serious brain infection is linked to the reactivation of the John Cunningham virus (JCV), and certain factors can increase your risk. Building on decades of research into immunosuppressive therapies, this page explains the role of JCV antibody testing and evaluation in assessing PML risk, helping you make informed decisions about your treatment.

Bridging General Principles to Specific Drug Risks

Building on the foundational understanding of biological risk, we now focus on the specific case of Tysabri (natalizumab), a monoclonal antibody used as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. The drug's prescribing information contains a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, but it has occurred in Tysabri-treated patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three factors are known to increase the risk of PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The drug is available only through a restricted distribution program called the TOUCH Prescribing Program because of the PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Evidence Linking Tysabri to PML

Clinical trial data show that PML occurred in three patients who received Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Two cases were observed among 1869 multiple sclerosis patients treated for a median of 120 weeks; these two patients had received Tysabri in addition to interferon beta-1a (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The third case occurred after eight doses in one of 1043 Crohn's disease patients evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These data establish a clear temporal relationship between Tysabri exposure and PML onset, with cases occurring after varying durations of treatment. The mechanistic pathway linking Tysabri to PML involves the drug's pharmacological action. Tysabri is an alpha-4 integrin antagonist that inhibits lymphocyte migration into the central nervous system. This immunosuppressive effect reduces immune surveillance, allowing reactivation of latent JCV in the brain. The JC virus then causes lytic infection of oligodendrocytes, leading to demyelination and the clinical syndrome of PML. The risk is highest in patients with anti-JCV antibodies, indicating prior exposure to the virus, and increases with longer treatment duration and prior immunosuppressant use.

Causation and Risk Context for Affected Patients

Regarding causation considerations for affected patients, the evidence supports a causal relationship between Tysabri and PML. The drug's label explicitly states that Tysabri increases the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The temporal relationship is established by clinical trial data showing PML onset during treatment. The biological plausibility is supported by the drug's mechanism of action reducing immune surveillance in the brain. For patients who develop PML while on Tysabri, the drug is considered a causative factor, though individual risk is modulated by the presence of anti-JCV antibodies, treatment duration, and prior immunosuppressant use. The adequacy of warnings regarding Tysabri and PML is addressed by the boxed warning, which is the strongest warning required by the FDA. The warning clearly states the increased risk of PML, identifies risk factors, and instructs on monitoring and withholding treatment. The TOUCH Prescribing Program further restricts access to ensure patients are informed of the risk. However, despite these warnings, PML continues to occur, highlighting the inherent risk of the drug. The timeline between Tysabri exposure and documented harm varies. In clinical trials, PML occurred after a median of 120 weeks in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The risk increases with longer treatment duration, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This indicates that PML can occur after relatively short exposure but becomes more likely with prolonged use. In summary, the evidence demonstrates that Tysabri causes PML through a well-understood mechanism involving reduced immune surveillance in the brain. The drug's labeling provides clear warnings about this risk, and clinical data establish a temporal relationship between exposure and harm. For affected patients, Tysabri is a causative factor, with risk modulated by individual patient characteristics and treatment duration.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the primary risk associated with Tysabri treatment?

The primary risk is progressive multifocal leukoencephalopathy (PML), a serious brain infection caused by the JC virus. Tysabri's prescribing information includes a boxed warning about this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What factors increase the risk of PML in Tysabri patients?

Three key factors increase PML risk: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Is there a causal relationship between Tysabri and PML?

Yes, the evidence supports a causal relationship. Clinical trials show a temporal link, and the drug's mechanism of reducing immune surveillance in the brain provides biological plausibility. The FDA boxed warning explicitly states that Tysabri increases PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.